In-stent Restenosis and Stent Thrombosis
Moscone West, 1st Floor
Tuesday, October 29, 2013, 3:30 PM–5:30 PM
Abstract nos: 447-485

TCT-447

Predictors and clinical implications of stent restenosis in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial
Salvatore Brugaletta1, Manel Sabate1, Victoria Martin-Yuste2, Monica Mazoni1, Angel Cequier3, Armando Bethencourt4, Josep Gomez Lara1, Andres Higuera2, Antonio Serra1, Rosana Hernandez-Antolín5, Marco Valjatija6, Vicente Mainar7, Maurizio Testilli8, Natalia Vazquez8, Peter den Heijer8, Patrick W. Serrvays8.
1Clinic Thorax Institute, Barcelona, Spain, 2University of Barcelona, Barcelona, Spain, 3Hospital Clinic, Barcelona, Spain, 4H Clinic Barcelona, Barcelona, Spain, 5Hospital de Bellvitge, Barcelona, Spain, 6Hospital Son Espases, Palma de Mallorca, Spain, 7Hospital Universitari de Bellvitge, Hospital de Llobregat, Spain, 8Hospital de Vigo, Vigo, Spain, 9Hospital de Sant Pau y Santa Creu, Barcelona, Spain, 10Hospital University Ramon y Cajal, Madrid, Spain, 11Universita degli Studi di Ferrara, Italy, 12University Hospital Bolognino Seriate, Bergamo, Italy, 13Hospital Juan Canalejo, A Coruña, Spain, 14Amboss Hospital Breda, Breda, NR, 15Thoraxcenter- Erasmus University, Rotterdam, Netherlands

Background: Few data are available about safety of second generation drug eluting stents in an all-comer ST elevation myocardial infarction (STEMI) population. We sought to investigate the predictors and clinical implications of 1-year stent thrombosis (ST) in patients with STEMI included the EXAMINATION trial.

Methods: TCT-447 is a RETROSPECTIVE ANALYSIS OF AN ALL-COMERS COHORT

Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please PCR provides good clinical outcomes demonstrated by the low TLR rate and low MACE rates at long-term follow-up.

TCT-449

COMPARISON OF Paclitaxel-ELUTING BALLOONS WITH DRUG-ELUTING STENTS FOR IN-STENT RESTENOSIS: A RETROSPECTIVE ANALYSIS OF AN ALL-COMERS COHORT
Guillaume Marquis Gravel1, Nicolas Noixse1, François Gobeil1, Louis-Mathieu Stevens2, Samer Massouër1
1University of Montreal, Montreal, Quebec

Background: The optimal treatment strategy for coronary in-stent restenosis (ISR) is unclear. Drug-eluting balloons (DEB) offer an alternative to drug-eluting stents (DES) by avoiding risks of stent thrombosis, and by lowering the risks of restenosis associated with standard balloon angioplasty and bare-metal stents. The objectives were to compare clinical outcomes of DEB versus second-generation DES for the treatment of ISR. The hypothesis was that DEB and DES would provide similar outcomes.

Methods: From December 2009 to November 2012, 102 coronary ISR were treated with a paclitaxel-eluting balloon in all-comer patients in a Canadian tertiary center. The comparator group consisted of a random sample of 100 patients with ISR treated with a second-generation DES in the same time period. Data was collected from medical files and telephone interviews. Mean follow-up was 16.9 months (222 patient-years).

Results: The composite clinical outcome of MACE (death from any cause, non-fatal myocardial infarction, or clinically-driven target lesion revascularization) occurred in 26% of patients in the DEB group compared to 24% in the DES group (p = 0.80). Freedom from MACE was similar between both groups after adjustment for confounding factors. Secondary outcomes are shown in the Table.

Conclusions: DEB appears as a safe and effective treatment for ISR as compared to second-generation DES. Our data suggest that clinical outcomes following revascularization with both devices are similar. Long-term clinical outcomes following ISR treatment with a DEB compared to second-generation DES remain to be prospectively studied.

Outcomes following treatment of in-stent restenosis

TCT-450

PREDICTORS OF ANGIOGRAPHIC OUTCOMES FOLLOWING IN-STEM RESTENOSIS TREATMENT WITH PACLITAXEL-ELUTING BALLOONS AND SECOND-GENERATION DRUG-ELUTING STENTS.
Guillaume Marquis Gravel1, François Gobeil1, Nicolas Noixse1, Louis-Mathieu Stevens2, Samer Massouër1
1University of Montreal, Montreal, Quebec

Background: Success of in-stent restenosis (ISR) treatment depends on angiographic lesion characteristics and co-morbidities. The optimal treatment option for ISR between drug-eluting balloons (DEB) or drug-eluting stents (DES) is not well known. The objectives were to assess risk factors for adverse outcomes following ISR treatment, and to evaluate the use of DEB in this setting.

Methods: Multivariate binary logistic regression was performed to assess predictors of treatment success following ISR treatment in a cohort including 102 patients treated with paclitaxel-eluting balloons and 100 random patients treated with a second-generation DES between December 2009 and November 2012 in a Canadian tertiary center (mean follow-up: 16.9 months; mean age: 65.2 ± 11 years). The effect of using a DES was adjusted for angiographic and clinical confounders. Indication for revascularization was non-ST-elevation acute coronary syndrome in 71% of cases in the DEB group as compared to 73% in the DES group (p = 0.37).

Results: The composite clinical outcome of MACE (death from any cause, non-fatal myocardial infarction, or clinically-driven target lesion revascularization) occurred in 26% of patients in the DEB group compared to 24% in the DES group (p = 0.80). Freedom from MACE was similar between both groups after adjustment for confounding factors. Secondary outcomes are shown in the Table.

Conclusions: DEB appears as a safe and effective treatment for ISR as compared to second-generation DES. Our data suggest that clinical outcomes following revascularization with both devices are similar. Long-term clinical outcomes following ISR treatment with a DEB compared to second-generation DES remain to be prospectively studied.

Outcomes following treatment of in-stent restenosis

TCT-448

Long-Term Clinical Results Of SeQuent Please Paclitaxel-Coated Balloon Angioplasty For The Treatment Of In-Stent Restenosis
Javier Benezech1, Ignacio Sanchez-Perez2, Fernando Lozano3, Felipe Higuera4, Natalia Pinilla1, Yasser Hessein1.
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for the treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or drug-eluting stent (DES) implantation. This study aims to evaluate the long-term safety and efficacy of the second-generation SeQuent Please PCB in coronary ISR in routine real-world practice.

Methods: Between May 2009 and April 2011, all consecutive patients with ISR lesions treated with the SeQuent Please PCB at our institution were prospectively included. Patients were followed up for 24 months by clinical observation. The primary endpoint was the clinically driven target lesion revascularization (TLR) rate at 24 months. The secondary endpoint was the rate of major adverse cardiac events (MACE: defined as a composite of cardiac death, myocardial infarction, and TLR) at 24 months.

Results: 48 patients with 52 ISR lesions (30 BMS, 22 DES) were included. Mean age was 66.2 ± 12.3 years. 75% were male and 50% were diabetics. The majority of patients presented with stable angina (63.5%). The target lesion was mainly located in the right coronary artery (46.1%) and the left anterior descending coronary artery (42.3%). The mean reference vessel diameter was 3.0 ± 0.5 mm and the mean target lesion length was 2.6 ± 2.2 mm. Coronary dissection occurred in 1 patient (1.9%), requiring additional stent implantation. Follow-up rate was 94.2%. The TLR rate was 5.8% after 24 months. Cumulative MACE at 24 months was 9.6%, with 1.9% cardiac death and 1.9% myocardial infarction. No vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty for BMS-ISR compared with DES-ISR (3.3% vs. 9.1%, p = 0.38). Baseline lesion characteristics and procedural data did not differ except for a longer lesion length for BMS-ISR compared with DES-ISR (25.4 ± 5.1 mm vs. 19.7 ± 6.9 mm, p = 0.008).

Conclusions: Success of in-stent restenosis (ISR) treatment depends on angiographic lesion characteristics and co-morbidities. The optimal treatment option for ISR between drug-eluting balloons (DEB) or drug-eluting stents (DES) is not well known. The objectives were to assess risk factors for adverse outcomes following ISR treatment, and to evaluate the use of DEB in this setting.

Methods: This MAMMAL STUDY was a PROSPECTIVE, SINGLE-CENTER, OPEN-LABEL, RANDOMIZED 1:1 controlled trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in STEMI patients. It included 1498 patients, randomized to EES (n = 751) or BMS (n = 747).

Results: At 1-year, definite/probable stent thrombosis, defined according to ARC criteria, occurred in 26 patients (1.73%), including 18 definite and 8 probable events. The incidence of ST was lower in patients treated with EES than in those treated with PBS (HR 0.30, 95% CI 0.13–0.69, p = 0.008). Patients with ST have higher 1-year rates of cardiac death (30.8% vs. 2.5%, p = 0.001), myocardial infarction (30.8% vs. 0.5%, p = 0.001) and target vessel revascularization (65.4% vs. 4.2%, p = 0.001) compared with those without. Independent predictors of 1-year definite/probable ST were BMS implantation at the index procedure (HR 3.41, 95% CI 1.35–8.60), ST segment resolution of at least 70% in the EKG post-PCI (HR 0.30, 95% CI 0.13–0.70) and Killip class on admission (HR 2.57, 95% CI 1.70–3.90).

Conclusions: ST had low frequency in the first year after implantation of EES/BMS in STEMI patients, but it is associated with adverse events. BMS implantation, lack of ST-segment resolution and high Killip class on admission were independent predictors of 1-year ST.